Gold bars to be exempt from tariffs, White House clarifies
On Monday, H.C. Wainwright maintained a positive stance on Evotec (NASDAQ:EVO) shares, reiterating a Buy rating and an $8.00 price target. The firm’s analyst praised the company’s recent performance, highlighting the significant quarter-over-quarter and year-over-year growth in the fourth quarter’s revenue, which amounted to €221.2 million. This figure not only represented approximately a 20% increase from the previous quarter but also a roughly 10% rise compared to the same period last year, exceeding the analyst’s expectations of €214.8 million. According to InvestingPro data, the stock has shown strong momentum with a 9% gain over the past week, though it remains 46% below its 52-week high of $7.77.
The Just Biologics segment was instrumental in driving the strong performance in the fourth quarter. Despite earlier predictions that Evotec would not see a recovery until 2025, the company seems to have made progress ahead of schedule. In 2024, Evotec initiated a three-step recovery strategy consisting of reset, review, and restart phases. The company has already completed the first two phases, achieving annualized recurring gross savings of €40 million by closing several sites to enhance cost efficiency and finalizing a strategic review to overhaul its business model. InvestingPro analysis indicates the company operates with a moderate debt level, maintaining a healthy current ratio of 1.98, which suggests adequate liquidity to support its transformation efforts.
Evotec’s management has set the stage for the final "restart" phase, anticipating revenue recovery in the second half of 2025. The company has issued guidance for 2025, expecting revenues to increase by 5-10% to reach between €840 million and €880 million. Additionally, research and development expenditures are projected to be in the range of €40-50 million, with adjusted EBITDA expected to hit €30-50 million. Looking further ahead, Evotec targets a revenue compound annual growth rate (CAGR) of 8-12% through 2028 and aims for an adjusted EBITDA margin above 20% by that year.
The endorsement of Evotec’s stock by H.C. Wainwright underscores the company’s successful navigation through challenges in the past 24 months and its capacity to exceed expectations. With the implementation of its recovery strategy and the setting of ambitious targets for the coming years, Evotec appears to be on a trajectory to achieve sustainable revenue growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.